Simple physician-prompting intervention drastically improves outcomes in CHD
April 1st 2002Creighton University, Omaha, NE-Despite the evidence that lipid-lowering drug therapy-especially with HMG-CoA reductase inhibitors (statins)-is known to save lives and help prevent subsequent events in coronary heart disease (CHD) patients, utilization of this class of drugs is erratic.
Read More
Biologics new and old may offer long-term management option for psoriasis
April 1st 2002An array of both existing and investigational biologic agents are showing efficacy in clearing psoriasis and may prove useful for long-term psoriasis management. So suggests a collection of studies presented at the 60th annual meeting of the American Academy of Dermatology, held recently in New Orleans.
Read More
Elimination of third-generation cephalosporins improves VRE infection rate control
April 1st 2002Three-year data have confirmed the effectiveness of a strategy that eliminated all third-generation cephalosporins from a formulary as a means to control the emergence of vancomycin-resistant enterococcus (VRE).
Read More
Physician receptivity to use of formulary-loaded PDAs is high, study finds
April 1st 2002Providing formulary information on PDA devices improves formulary compliance and is gaining in physician acceptance as well. These were the findings of a 4-month pilot program involving 104 Connecticut-based physicians conducted by ePocrates and AdvancePCS.
Read More
Applying multiattribute utility technology to the formulary evaluation process (PDF)
April 1st 2002Seldom are the attributes of drugs under formulary consideration conveniently measured on the same scale, and if they are, they typically do not carry the same weight in a decision. Fortunately, application of Multiattribute Utility Technology (MAUT) provides a way to incorporate several valued attributes of disparate weights into a unitary measure for the purpose of evaluating options. This month's column presents the core elements of MAUT and explores its use in the drug evaluation process through a mock formulary committee example.
Read More
Rosuvastatin: A new HMG0CoA reductase inhibitor for hypercholesterolemia (PDF)
April 1st 2002Rosuvastatin is an investigational HMG-CoA reductase inhibitor expected to gain FDA approval later this year for treatment of hypercholesterolemia. It has significantly exceeded atorvastatin, pravastatin, and simvastatin in reducing LDL cholesterol in clinical trials. This Focus article reviews those trials as well as rosuvastatin's pharmacologic and safety profiles in an effort to delineate its likely role in cholesterol-reducing therapy.
Read More
Why physicians start or stop prescribing a drug: Literature review and formulary implications (PDF)
April 1st 2002These authors report on their literature search of studies assessing the impact of factors influencing the diffusion of new drug therapies and physicians' adoption and eventual relinquishment of those therapies. They specifically explore how their finds can help better align physician prescribing with formulary objectives.
Read More
A perfect fit Coordinated care is vital to managing depression
April 1st 2002Seeking help for depression is finally losing some of its stigma. The National Association of Psychiatric Health Systems (NAPHS) 2001 Annual Survey Report, "Trends in Behavioral Healthcare Systems," says both hospital occupancy and outpatient visits for behavioral health problems increased 11% and nearly 12%, respectively, between 1999 and 2000.
Read More
Health plans can substantially boost their use of generics, study concludes
March 2nd 2002Optimal management can raise health plans' generic utilization rates from the current average of 34.5% to 51%. So concludes a new study from Stanley Wallack, PhD, and other researchers from Brandeis University.
Read More